Abstract: This invention relates to compositions for inhibiting apoptosis, containing one to all components of: (a) an APO-1-inhibiting compound; (b) a compound inhibiting and catching, respectively, the APO-1 ligand; and (c) a compound inhibiting the intracellular APO-1 signalling pathway, the component(s) being not considered foreign in an individual, as well as conventional excipients. Furthermore, this invention relates to compounds suitable for inhibiting apoptosis and having at least one extracellular APO-1 domain and a carrier, the domain(s) and the carrier being not considered foreign in an individual.

Abstract: The present invention relates to the use of inhibitors of the CD95 ligand/receptor system for the manufacture of a medicament for the treatment of neurological disorders or injuries in a mammal, particularly for the treatment of spinal cord injury, more particularly for the treatment of paraplegia.

Abstract: The present invention relates to p53 binding regions on a CD95 receptor DNA and to the application of the p53 binding regions to influence apoptosis and/or identify suitable substances therefor.

Abstract: An optical measuring device includes at least one optical sensor, an optical waveguide connected to the optical sensor, and an evaluation unit. The optical measuring device is intended for an electrical machine including at least one conductor that is pressed into a groove of a base body, the groove having two groove lateral walls. The optical sensor and a part of the optical waveguide that is located in a proximity of the sensor are disposed in the area of the groove on a narrow side of the conductor that faces away from both groove lateral walls.

Abstract: The invention relates to a protein for regulating apoptosis and to a nucleic acid encoding the protein. The protein and nucleic acids are useful in the regulation of apoptosis, and in methods for diagnosing or detecting apoptosis. The invention also relates to antibodies directed against the protein.

Abstract: Disclosed is a method for determining whether a test compound is effective for a chemotherapy. The inventive method comprises the following steps: a) a DNA sequence is provided, whereby said sequence comprises site AP-1 represented in FIG. 5A as a constituent of a promoter, preferably promoter CD95L, which is functionally linked to a reporter gene or the CD95L gene, b) the DNA sequence a) is brought into contact with the test compound in a cellular assay, and c) activation of the promoter is determined, said activation indicating that the test compound is effective for a chemotherapy.

Abstract: The invention relates to medicaments which contain one or more compounds inhibiting the biological effects of TNF-&agr; and CD95L, e.g. by blocking the binding of these ligands to their natural receptors thus eliminating signal transduction. These compounds are preferably a neutralizing anti-TNF-&agr; antibody and a neutralizing anti-CD95L antibody. The invention also relates to the use of the above compounds for preventing or treating an apoplectic stroke or heart attack.

Abstract: An optical measuring device includes at least one optical sensor, an optical waveguide connected to the optical sensor, and an evaluation unit. The optical measuring device is intended for an electrical machine including at least one conductor that is pressed into a groove of a base body, the groove having two groove lateral walls. The optical sensor and a part of the optical waveguide that is located in a proximity of the sensor are disposed in the area of the groove on a narrow side of the conductor that faces away from both groove lateral walls.

Abstract: The invention relates to a method for inhibiting CD95-independent apoptosis, comprising the following steps: (a) blocking the bonding of HIV-1 gp120 on receptors CD4 and/or CXCR4 or of a factor competing for this bonding, and/or (b) inhibiting the signal path induced by the bonding of (a). The invention also relates to a system for identifying substances which can be utilized for inhibiting CD95-independent apoptosis.

Abstract: The invention relates to a protein for regulating apoptosis and to a nucleic acid encoding the protein. The protein and nucleic acids are useful in the regulation of apoptosis, and in methods for diagnosing or detecting apoptosis. The invention also relates to antibodies directed against the protein.

Abstract: The present invention relates to p53 binding regions on a CD95 receptor DNA and to the application of the p53 binding regions to influence apoptosis and/or identify suitable substances therefor.

Abstract: The invention concerns an ultrasonic transducer for the determination of the acoustic power of an ultrasonic field (1) focused at a point (F). According to the invention, an ultrasonic transducer 2 contains a support structure (4) which has the shape of a spherical cup and whose center coincides with the focus (F) of the focused ultrasonic field (1), and a piezoelectric polymer foil (6) equipped on its respective surfaces (62, 64) with a conductive layer (8) is attached to said support structure. These measures ensure that the acoustic charge vibrations within the area formed by the piezoelectric polymer foil (6) are at least approximately in phase and that the respective surface charge vibrations can be measured with the aid of a single, continuous electrode without partial mutual cancellation.

Abstract: The invention concerns a method for surveying the focal point (F, F') of a focussed ultrasonic field (8, 14) and an apparatus for carrying out the method. According to the invention an ultrasonic field (4, 12) produced by an ultrasonic transmitter (2) is measured at several sites in a plane in the path of the waves at the site of the imaging device (6). The values determined at these sites are compared with given reference values for which the position of the focus is known. In an advantageous device, one surface of the imaging device (6) is equipped with several piezoelectric transducers.